Skip to main content

Comparative efficacy and safety of systemic therapies for moderate-to-severe atopic dermatitis in adults: a systematic review of randomized controlled trials

In brief

Upadacitinib had the highest observed skin-clearance response in trial comparisons

Across 25 randomized trials, 73% of adults taking upadacitinib achieved at least 75% improvement in eczema severity by 16 weeks, the highest observed response among the reviewed therapies. These are cross-trial comparisons, not direct evidence that one treatment is superior; differences in trial design limit rankings, and long-term comparative data remain lacking.

Journal
Frontiers in immunology (Q1)
Published
30 October 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Vasiliki Pikoula, Efterpi Zafiriou, Anthony Bewley, Andrea Carugno, Ignasi Figueras Nart, Emily Kelly, et al.
PMID
43031784
DOI
10.3389/fimmu.2026.1985846

Why clinicians should know about it

  • Picked for Immunology and Allergy (top studies of the week, 15 November 2026): Systematic review of biologics and JAK inhibitors for atopic dermatitis
  • Picked for Dermatology (paper of the day, 15 November 2026): Systematic comparison of approved systemic therapies for adult atopic dermatitis

Abstract

BACKGROUND: Atopic dermatitis (AD) is a common, chronic inflammatory skin condition, and patients with moderate-to-severe disease often require systemic therapy. Since 2017, targeted systemic agents, biologics and Janus kinase (JAK) inhibitors, have expanded treatment options available, but comparative evidence remains limited by heterogeneous trial design, outcome reporting, and follow-up duration. OBJECTIVE: To systematically review the efficacy and safety of European Medicines Agency (EMA)-approved systemic therapies for moderate-to-severe AD in adults. METHODS: Following PRISMA 2020 guidelines, we searched PubMed/MEDLINE, Embase and Web of Science for randomized controlled trials evaluating EMA-approved biologics (dupilumab, tralokinumab, lebrikizumab, nemolizumab) and JAK inhibitors (upadacitinib, abrocitinib, baricitinib) at recommended adult doses. The primary outcome was the proportion of patients achieving EASI-75 at the primary trial endpoint (12-16 weeks). Due to substantial clinical and methodological heterogeneity, a structured narrative synthesis was conducted rather than a meta-analysis. RESULTS: Twenty-five RCTs met inclusion criteria. At EMA-recommended doses, EASI-75 responses ranged from 44% to 69% for dupilumab, 60.6% for lebrikizumab, 25-64% for tralokinumab, and 49.1% for nemolizumab (combination-therapy data only). Among JAK inhibitors, upadacitinib showed the highest observed response rate (73.0% at 16 weeks), followed by abrocitinib (64.6% at 12 weeks) and baricitinib (17.9-48.0%). Placebo response rates ranged from 6% to 36% and were consistently higher in combination-therapy trials. Any adverse event occurred in 45.2% (abrocitinib 100 mg) to 82.46% (nemolizumab) of patients, with serious adverse events generally low across therapies. CONCLUSION: EMA-approved systemic therapies for moderate-to-severe AD demonstrate meaningful short-term efficacy and acceptable safety. However, treatment selection should remain individualized given cross-trial heterogeneity and the current absence of long-term comparative data. Further head-to-head trials and real-world evidence are needed to optimize treatment sequencing. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD420251102911.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.